5-Amino-1MQ
Metabolic / Fat Loss Compound (NNMT Inhibitor)researchAlso known as: 5-amino-1-methylquinolinium, NNMT inhibitor
A small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that promotes fat loss by increasing NAD+ levels and cellular energy metabolism, available as an oral compound.
Overview
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a key role in cellular metabolism and energy expenditure. While technically not a peptide, it is commonly discussed alongside metabolic peptides due to its use in peptide-based fat loss protocols. NNMT is highly expressed in adipose tissue, and its overactivity is associated with obesity, metabolic syndrome, and reduced NAD+ availability. By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, enhances cellular energy metabolism, and promotes the conversion of white adipose tissue toward a more metabolically active phenotype. Developed at the University of Texas Health Science Center, preclinical studies showed significant fat loss in diet-induced obese mice without changes in food intake, exercise, or lean mass. Its oral bioavailability makes it unique among fat-loss compounds in this space.
Mechanism of Action
5-Amino-1MQ acts through NNMT inhibition: (1) Blocks NNMT enzyme activity, preventing methylation and degradation of nicotinamide (NAM); (2) Increases intracellular NAD+ levels by preserving the NAM precursor pool; (3) Activates SIRT1 and other sirtuins through elevated NAD+, enhancing fat oxidation; (4) Promotes browning of white adipose tissue, increasing thermogenesis; (5) Reduces expression of lipogenic genes in adipocytes; (6) Enhances mitochondrial biogenesis and cellular energy expenditure; (7) Increases SAM (S-adenosylmethionine) availability, potentially affecting methylation reactions.
Molecular Formula
C10H13N2O
Molecular Weight
177.22 g/mol
Sequence
N/A — small molecule, not a peptide
Dosage Protocols
Dose Range
50mg – 100mg
Frequency
Once daily
Route
oral
Cycle Length
8-12 weeks
Oral capsule form. Take in the morning with or without food. Some protocols use up to 150mg/day. Can be stacked with other fat-loss peptides (AOD 9604, HGH Fragment). No injection required.
Source: Clinic protocols and preclinical extrapolation
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
50mg capsules, 30ct
Last Updated
2026-02
Oral capsule form. Available from research peptide vendors. Newer compound with limited commercial availability.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Mild GI discomfort | mild |
| Headache | mild |
| Insomnia | mild |
| Unknown long-term effects | unknown |
Pros & Cons
Oral bioavailability — no injections required, making it highly convenient
Promotes fat loss without affecting food intake, exercise requirements, or lean muscle mass
Increases NAD+ levels, providing potential anti-aging and metabolic benefits beyond fat loss
Novel mechanism distinct from stimulants, GLP-1 agonists, or thermogenics
No human clinical trials — all efficacy data from animal studies
Not technically a peptide — mechanism and long-term effects less familiar to the peptide community
NNMT inhibition may have unintended consequences on methylation and other metabolic pathways
Relatively expensive and available from limited sources
Research Studies
🩸 Blood Work
No specific bloodwork requirements reported for this peptide. General health panels are always recommended before starting any peptide protocol.
Legal Status
Not FDA-approved. Available as a research chemical. Increasingly offered by compounding pharmacies and peptide clinics. No specific scheduling or restrictions in most jurisdictions.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Collagen Peptides
Bioactive peptide fragments derived from hydrolyzed collagen protein that support skin elasticity, joint health, bone density, hair/nail growth, and gut lining integrity through stimulation of endogenous collagen synthesis.